Vibration Therapy, Healthy Volunteer Study, Hypoactivity
Conditions
Keywords
hypoactivity, neuromuscular deconditionning, Vibration
Brief summary
Muscle deconditioning, characterized by a loss of muscle mass and strength, is a frequent consequence of prolonged lower limb unloading. Beyond muscle mass loss, reduced neural drive contributes significantly to strength decline, highlighting the need for interventions targeting neuromuscular function during immobilization. Focal muscle vibration (FMV) has shown promise in modulating neuromuscular excitability by activating muscle spindle afferents and inducing cortical adaptations. Chronic use of FMV has been associated with significant strength gains and improved neural command. This makes FMV an effective rehabilitation tool. Its simplicity and non-invasiveness further make it a practical countermeasure.
Detailed description
This study hypothesizes that a 10-day FMV protocol can induce neural adaptations to limit strength loss during unilateral lower limb suspension, offering a novel strategy against neuromuscular function decline.
Interventions
DEVICEFocal muscle vibration
focal muscle vibration sessions, using small and portable vibrator devices.
DEVICENO Focal muscle vibration
The control group will not receive any intervention.
Sponsors
Centre Hospitalier Universitaire de Saint Etienne
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
19 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
* Men and women. * Aged 18 to 45 years. * Body Mass Index (BMI) between 20 and 25 kg/m². * Engaging in at least 1.5 hours per week of physical activity (e.g., brisk walking, running, swimming, cycling). * Provided informed consent after receiving detailed information about the study. * Affiliated with or beneficiaries of a social security system
Exclusion criteria
* Chronic cardiovascular, neuromuscular, bone, metabolic, and/or inflammatory disorders. * Personal history and/or risk factors for thrombosis. * Use of antidepressant medications. * Use of neuroactive substances likely to alter corticospinal excitability (e.g., hypnotics, antiepileptics, psychotropics, muscle relaxants) during the study. * Recent bone or ligament trauma within the past 12 months. * Inability to perform the physical efforts required for the study. * Recent participation in a sporting competition or intense, unusual physical activity within the past month. * Corticosteroid treatment within the past 3 months. * Any skin lesions at the planned vibrator application site. * Simultaneous participation in another interventional medical study. * Pregnant or breastfeeding women. * Individuals unable to understand the purpose and conditions of the study or unable to provide informed consent. * Individuals deprived of liberty or under guardianship
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Isometric force measurement | Day 1, 7, 14, 28, 33 | Maximal isometric force (% decrease) in knee extension of the immobilized leg will be evaluated |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Jumping performance measurement | Day 1, 7, 14, 28, 33 | Jumping performance (height, in cm), assessed in vertical jump tests (Squat Jump and Counter Movement Jump). |
| Postural balance measurement | Day 1, 7, 14, 28, 33 | Postural balance performance (displacement of center of pressure, in mm), assessed in a unipodal postural balance test performed on a strength platform |
| Neuromuscular fatigue measurement | Day 1, 7, 14, 28, 33 | Neuromuscular fatigue (decrease in maximum voluntary force (in %), assessed during a fatigue protocol consisting of quadriceps muscle contractions at incremental force levels. |
| Force-velocity-endurance measurement | Day 1, 7, 14, 28, 33 | Force-velocity-endurance profile, assessed during an effort performed on a cycloergometer at linearly decreasing power values. |
| Voluntary activation level evaluation | Day 1, 7, 14, 28, 33 | Voluntary activation level (in %), determined by the force increment obtained following stimulation during a maximal voluntary isometric contraction. |
| Maximum voluntary force measurement | Day 1, 7, 14, 28, 33 | Maximum voluntary force (Nm) in knee extension, assessed in isometric (for the immobilized leg and also for the contralateral leg), concentric (+60°/s and +180°/s) and eccentric (-60°/s) conditions. |
| Spinal excitability evaluation | Day 1, 7,14 , 28, 33 | Spinal excitability (i.e. spinal reflexes, in mV), assessed by recording EMG responses evoked by electrical stimulation of the lumbar vertebrae. |
| Cortical activation of sensorimotor areas measurement | Day 1, 7, 14, 28, 33 | Cortical activation of sensorimotor areas, assessed by recording the electroencephalographic (EEG) signal during submaximal isometric contractions. |
| Muscle volume measurement | Day 1, 7, 14, 28, 33 | Muscle volume will be assessed by ultrasound of the thigh muscles (in cm2). |
| Determination of plasma molecular markers of bone and muscle remodeling | Day 1, 7, 14, 28, 33 | Assessment of blood factors of nerve (BDNF) and muscle remodeling (circulating steroids, insulin, GH, IGF-1, myostatin, activinA, follistatin). |
| Plasma molecular markers of thrombotic risk evaluation | Day 1, 7, 14, 28, 33 | Plasma molecular markers of thrombotic risk will be assessed by blood sampling followed by assay of HSP47 and D-dimer factors. |
| Cortico-spinal excitability measurement | Day 1, 7, 14, 28, 33 | Cortico-spinal excitability, assessed by electromyographic responses (motor evoked potentials, in mV) evoked by transcranial magnetic stimulation (TMS). |
Countries
France
Contacts
Primary ContactLEONARD FEASSON, PHD
Outcome results
None listed